Plaque Psoriasis, Skin Diseases, Skin Diseases, Papulosquamous
Conditions
Keywords
Plaque Psoriasis
Brief summary
To compare the safety and efficacy profile of AM001 Cream and its vehicle in the treatment of plaque psoriasis.
Interventions
Cream, 2x daily for 12 weeks
DRUGPlacebo of AM001 Cream
Cream, 2x daily for 12 weeks
Sponsors
AmDerma
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Subjects must provide Institutional Review Board (IRB) approved written informed consent. 2. Subjects must be male or female, at least 18 years of age. 3. Subjects with a definite diagnosis of plaque psoriasis that is clinically active (for at least 3 months), involving at least 3% and up to 20% of the body surface area (not including the scalp, face, hands, feet, and intertriginous areas). 4. Subjects with an Investigator's Global Assessment (IGA) of disease severity of at least moderate severity (score ≥ 3) as an overall assessment. 5. Subjects with a minimum plaque elevation of at least moderate severity (PASI grade ≥ 3) at the target lesion site. 6. If females of childbearing potential, the subject must have a negative urine pregnancy test, and must have been using an acceptable form of birth control for at least two months prior to Screening and are willing to continue birth control throughout the study. 7. Subjects must be willing and able to understand and comply with the requirements of the study, apply the study medication as instructed, return for the required treatment period visits, comply with therapy prohibitions, and be able to complete the study. 8. Subjects must be in good health, as confirmed by medical history and physical exam, and free from any clinically significant disease/condition, other than plaque psoriasis, that might interfere with the study evaluations. 9. Subjects must be willing to limit sun exposure overall. Subjects are prohibited from sunbathing or intentional tanning or intense sun exposure including the use of tanning booths/lights or other artificial UV light sources throughout the study.
Exclusion criteria
1. Female subjects who are pregnant, nursing, or planning a pregnancy within the study participation period. 2. Subjects who have a current diagnosis of guttate, pustular, inverse, exfoliative, or erythrodermic psoriasis. 3. Subjects who have a history of psoriasis unresponsive to topical treatments. 4. Subjects who have a history of a disorder that may interfere with the evaluation of plaque psoriasis (e.g., atopic dermatitis, contact dermatitis, tinea corporis, cutaneous lymphoma, etc.). 5. Presence of pigmentation, extensive scarring, or pigmented lesions in the treatment areas, which could interfere with the rating of efficacy parameters. 6. Subjects with unstable medical disorders, life-threatening disease, or current malignancies. 7. Subjects with clinically significant ECG or laboratory abnormalities at Screening (as determined by the Investigator). 8. Subjects who are immunosuppressed. 9. Subjects who have a history of allergy or a known hypersensitivity to any component of the study medication. 10. Subjects who have been treated with any systemic steroids within the 4 weeks prior to the study entry. 11. Subjects who have been treated with systemic or photo antipsoriatic therapies/drugs within 4 weeks prior to study entry including methotrexate, cyclosporine, acitretin and other oral retinoids, broadband or narrowband UVB, PUVA, home or professional tanning lights or other nonprescription UV light sources, photodynamic therapy (PDT), lasers, mycophenalate mofetil (MMF), thioguanine, hydroxyurea, sirolimus, azathioprine, 6-mercaptopurine (6-MP), or etanercept. 12. Subjects who have been treated with biologic therapy other than etanercept within 8 weeks prior to study entry. Vaccines will not be considered an exclusionary biologic treatment. 13. Subjects who have been treated with any topical anti-psoriatic (e.g., salicylic acid, anthralin, tar, etc.,) any topical corticosteroid medications, topical retinoids (e.g., tazarotene, tretinoin), topical Vitamin D analogs (e.g., calcipotriene), topical immunosuppressants (e.g., tacrolimus, pimecrolimus) within 2 weeks prior to study entry. 14. Subjects who have been treated with lithium, antimalarial agents, or quinidine within the 4 weeks prior to study entry. 15. Subjects who have received radiation therapy and/or anti-neoplastic agents, or taken any immunosuppressant medication within 3 months prior to study entry.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Investigator's Global Assessment of Disease Severity (IGA) | Week 12 | An overall assessment of disease severity will be performed at each study visit. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Target Lesion Psoriasis Area Severity Index (PASI) | 12 Weeks | Erythema, Scaling and Plaque Elevation of the target lesion will be scored at baseline and at each subsequent study visit. |
| Body Surface Area (BSA) | 12 Weeks | The % BSA of all treatable psoriatic lesions and regions will be recorded at baseline and at week 12. |
| Target Lesion Area | 12 Weeks | The target lesion area will be measured at baseline and each-post-baseline visit. |
| Dermatology Life Quality Index (DLQI) | 12 Weeks | Measured at baseline and week 12. |
| Pharmacokinetics | 2 Weeks | Systemic absorption will be determined in a subgroup. |
Countries
United States
Outcome results
None listed